Neil Riordan, P.A., Ph.D. is one of the early pioneers and experts in applied stem cell research. Riordan founded publicly traded company Medistem Laboratories (later Medistem Inc.), which was acquired by Intrexon in 2013.

He is the founder and chairman of Medistem Panama, Inc., a leading adult stem cell laboratory and research facility located in the Technology Park of the prestigious City of Knowledge in Panama City, Panama.

Riordan is founder, chairman and chief science officer of the Stem Cell Institute in Panama, which specializes in the treatment of human diseases and conditions with adult stem cells, primarily human umbilical cord tissue-derived mesenchymal stem cells.

He is co-founder and chief science officer for the Riordan Medical Institute (RMI). Located in the Dallas-Fort Worth area city of Southlake, Texas, RMI specializes in the treatment of orthopedic conditions with autologous bone marrow-derived stem cells combined with amniotic and umbilical cord tissue products developed by Riordan.

He is also the founder of Aidan Products, which provides health care professionals with quality nutraceuticals. Riordan’s team developed the product Stem-Kine, the only nutritional supplement that is clinically proven to increase the amount of circulating stem cells in the body for an extended period of time.

He is founder and chief scientific officer for Signature Biologics in Dallas, Texas. Signature biologics develops, manufactures, and distributes human placental-derived products including Signature Cord, a human umbilical cord tissue-derived product and Signature Matrix, an amniotic tissue-based product.

Riordan is also affiliated with Southwest College of Naturopathic Medicine (SCNM) in Tempe, Arizona where the Neil Riordan Center for Regenerative Medicine is accelerating the development of regenerative medicine, particularly autologous stem cell therapy, which utilizes a patient’s own stem cells to promote healing, reduce inflammation and stimulate tissue repair. People with acute and chronic pain, including elite athletes, may benefit from the growth factors, natural anti-inflammatory activity, and regenerative properties of autologous stem cell therapy. The Neil Riordan Center for Regenerative Medicine is staffed by an interdisciplinary team of physicians and housed in SCNM’s LEED Platinum certified Community Commons.

Riordan has published more than 70 scientific articles in international peer-reviewed journals. In the stem cell arena, his colleagues and he have published more than 20 articles on multiple sclerosis, spinal cord injury, heart failure, rheumatoid arthritis, Duchenne muscular dystrophy, autism, and Charcot-Marie-Tooth syndrome. In 2007, Riordan’s research team was the first to discover and document the existence of mesenchymal-like stem cells in menstrual blood. For this discovery, his team was honored with the “Medical Article of the Year Award” from Biomed Central. Other notable journals in which Riordan has published articles include the British Journal of Cancer, Cellular Immunology, Journal of Immunotherapy, and Translational Medicine.

In addition to his scientific journal publications, Riordan has authored two books about mesenchymal stem cell therapy: Stem Cell Therapy: A Rising Tide: How Stem Cells Are Disrupting Medicine and Transforming Lives and MSC (Mesenchymal Stem Cells): Clinical Evidence Leading Medicine’s Next Frontier. Riordan has also written two scientific book chapters on the use of non-controversial stem cells from placenta and umbilical cord.

Riordan is an established inventor. He is the inventor or co-inventor on more than 25 patent families, including 11 issued patents. His team collaborates with a number of universities and institutions, including National Institutes of Health, Indiana University, University of California, San Diego, University of Utah, University of Western Ontario, and University of Nebraska.

He has made a number of novel discoveries in the field of cancer research since the mid-1990s when he collaborated with his father, Hugh Riordan, on the effects of high-dose intravenous vitamin C on cancer cells and the tumor microenvironment. This pioneering study on vitamin C’s preferential toxicity to cancer cells notably led to a 1997 patent for the treatment of cancer with vitamin C. In 2010, Riordan was granted an additional patent for a new cellular vaccine for cancer patients.

Riordan earned his Bachelor of Science at Wichita State University and graduated summa cum laude. He received his master’s degree at the University of Nebraska Medical Center. Riordan completed his education by earning a doctorate in health sciences at Medical University of the Americas.